Danesh Alam
Psychiatry · Winfield, ILNPI 1043227200
Payments from drug & device makers
Across 475 payments — averaging $5585.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$581K
- Indivior Inc.$563K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$516K
- Janssen Research & Development, LLC$449K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$374K
- Acadia Pharmaceuticals Inc$78K
- plus $92K from 9 others
Across 20 payments — averaging $178.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$1K
- Acadia Pharmaceuticals Inc$845
What the payments were for
- Consulting fees$33,40989%
- Travel & lodging$2,8177%
- Food & beverage$1,3554%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 105 | $580,935 |
| Indivior Inc. | 161 | $562,872 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 13 | $516,109 |
| Janssen Research & Development, LLC | 46 | $449,150 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 50 | $374,140 |
| Acadia Pharmaceuticals Inc | 14 | $78,101 |
| Genentech, Inc. | 4 | $26,979 |
| Alkermes, Inc. | 39 | $22,833 |
| Johnson & Johnson | 20 | $13,111 |
| Eli Lilly | 1 | $11,219 |
| Livanova USA, Inc. | 5 | $8,000 |
| MDD US Operations, LLC | 11 | $5,145 |
| Novartis | 2 | $2,817 |
| E.r. Squibb & Sons, L.L.C. | 3 | $1,762 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$12,840
- VIVITROL$7,500
- Lucemyra/Lofexidine$4,969
- VNS Therapy$316
How this compares
$2,653,190 in reported general payments places this provider in the 95th percentile of 1,344 psychiatry providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 12 | $3,291 |
| Trazodone Hcl | 21 | $347 |
| Fluoxetine Hcl | 17 | $39 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Indivior Inc.Suboxone | $562,872 | $3,29112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,344 psychiatry providers in Illinois.
Other psychiatry in Winfield
- Jeffrey RossNorthbrook$10.8M
- Yuhwen ChowChicago$8.5M
- Mark LermanNorthbrook$4.5M
- John ZajeckaSkokie$2.5M
- Riaz BaberNaperville$2.4M
- Michael GreenbaumLibertyville$2.2M
- Sandeep GaonkarNaperville$1.8M
- Jon GrantChicago$1.4M
- David KempOak Lawn$1.4M
- Jeffrey RadoChicago$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.